People's Welfare Pharmaceutical: Subsidiary's Application for Drug Marketing Approval Accepted

Renfu Pharmaceuticals announced that its holding subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., recently received the Drug Registration Approval Application Acceptance Notice issued by the National Medical Products Administration for the registration and market approval of methylphenidate hydrochloride and right-phenylamine capsules. The drug is used to treat attention deficit hyperactivity disorder in adults and pediatric patients aged 6 and above, as well as moderate to severe binge eating disorders in adults. The indications applied for by Yichang Renfu this time are for attention deficit hyperactivity disorder in adults and pediatric patients aged 6 and above. Currently, there is no domestic market for this drug, and no related products have been approved for import. Yichang Renfu has invested approximately RMB 90 million in research and development for this project. The acceptance of the drug registration and market approval application by the National Medical Products Administration signifies that the domestic production and registration work for this product has entered the evaluation phase.